Chinese medicine composition for treating or preventing heart failure or heart insufficiency

Through the extraction and purification of ginseng, salvia miltiorrhiza and yamsula, a traditional Chinese medicine composition for the treatment of cardiac insufficiency or heart failure was prepared, which solved the problem of lack of effective Chinese medicine compound prescriptions in the prior art, and achieved significant improvement of cardiac function and reduced myocardial injury. effect.

CN116747257BActive Publication Date: 2024-12-03XIYUAN HOSPITAL OF CHINA ACAD OF CHINESE MEDICAL SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310780614.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-06-28
Publication Date
2024-12-03
Estimated Expiration
2043-06-28

AI Technical Summary

Technical Problem

The existing technology lacks effective Chinese medicine compound varieties for the treatment and prevention of cardiac insufficiency or heart failure. The market is urgently demanding to develop a targeted Chinese medicine drug with accurate efficacy, significant, excellent process and stable drug quality.

Method used

The compositions of ginseng, salvia miltiorrhiza and yhusuo are extracted by ethanol or aqueous ethanol solution and the large pore adsorption resin is purified, and the traditional Chinese medicine composition is mixed to treat and prevent cardiac insufficiency or heart failure.

Benefits of technology

Through the effects of invigorating qi, promoting blood circulation, removing blood stasis and relieving pain, this traditional Chinese medicine composition significantly improves heart function, reduces myocardial damage and fibrosis, and slows down the development of heart failure. It has good efficacy and safety. It is suitable for coronary heart disease and myocardial infarction Cardiac protection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004310732120000111
    Figure BDA0004310732120000111
  • Figure BDA0004310732120000121
    Figure BDA0004310732120000121
  • Figure BDA0004310732120000122
    Figure BDA0004310732120000122
Patent Text Reader

Abstract

The present application discloses a Chinese medicine composition prepared from Chinese medicinal materials including ginseng, salvia miltiorrhiza and corydalis yanhusuo, and use of the Chinese medicine composition in preparing a medicine for treating and / or preventing heart failure or heart insufficiency.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of traditional Chinese medicine, and in particular relates to a traditional Chinese medicine composition for treating and / or preventing heart failure or heart failure and a pharmaceutical preparation containing the traditional Chinese medicine composition. Background Art

[0002] Heart failure is a symptom caused by a decrease in the contractile function of the myocardium due to various reasons, which reduces the forward blood discharge of the heart and causes blood stasis in the systemic circulation or pulmonary circulation. Heart failure (HF) is a group of clinical syndromes caused by abnormal cardiac structure and function, which impairs ventricular filling or ejection capacity, causing blood stasis in the venous system and / or insufficient perfusion of the arterial system. Compared with patients with ordinary coronary heart disease, patients with heart failure and heart failure have a high risk of death and a poor prognosis. With the continuous popularization of percutaneous coronary intervention (PCI) technology, the in-hospital mortality rate of AMI patients has been significantly reduced. However, heart failure and heart failure still have a high incidence rate, and the current status of their prevention and treatment in my country is still not optimistic.

[0003] With the deepening of basic and clinical research on heart failure, heart failure is no longer considered a simple hemodynamic disorder. More importantly, it is a clinical syndrome that promotes the continuous development of heart failure due to the participation of multiple neurohumoral factors. The new concept believes that heart failure can be divided into two stages: asymptomatic and symptomatic. The former has objective evidence of ventricular dysfunction (such as reduced left ventricular ejection fraction), but no typical symptoms of congestive heart failure. The heart function is still grade I of the New York Heart Association (NY-HA), which is the early stage of symptomatic heart failure. If it is not effectively treated, it will sooner or later develop into symptomatic heart failure, that is, heart failure. Heart failure can be classified according to different indicators. According to the left ventricular ejection fraction, heart failure can be divided into three categories. For patients with heart failure with reduced ejection fraction, the left ventricular ejection fraction is less than 40%. At this time, the ejection function is significantly reduced, indicating that the patient's contractile function is severely damaged, which is a more common type of heart failure. If the ejection fraction is between 40% and 50%, it is called heart failure with an intermediate ejection fraction range. If the ejection fraction is greater than 50%, it is within the normal range of ejection fraction, which is called heart failure with preserved ejection fraction.

[0004] Depending on the severity of heart failure, it can be divided into acute heart failure and chronic heart failure. If it is sudden and the symptoms are very severe, it is called acute heart failure; if it enters a chronic and relatively stable stage, it is called chronic heart failure. In addition, according to different parts, heart failure can be divided into left heart failure and right heart failure. If both the left and right heart fail at the same time, it can be called total heart failure.

[0005] There is currently no effective treatment for heart failure to improve the long-term prognosis of patients. The first choice of treatment is loop diuretics to reduce the burden on the heart; if tissues and organs are hypoperfused, positive inotropic drugs such as beta-agonists, digitalis drugs, phosphodiesterase inhibitors, calcium sensitizers, etc. can be considered. Conventional treatment drugs for patients with heart failure with reduced ejection fraction (left ventricular ejection fraction <40%) mainly include diuretics, vasodilators, positive inotropic drugs, vasoactive drugs, neuroendocrine hormone regulators (ACEI / ARB / ARNI, beta-blockers, MRA), etc. However, the re-hospitalization rate and mortality rate of patients with heart failure with reduced ejection fraction are still high. Patients with mildly reduced heart failure (left ventricular ejection fraction of 40%-50%) account for 7.5% to 25.0% of heart failure patients. Since heart failure with mildly reduced ejection fraction has certain similarities with heart failure with reduced ejection fraction, drugs for treating heart failure with reduced ejection fraction also have certain efficacy on heart failure with mildly reduced ejection fraction, and the effect is better than that on heart failure with preserved ejection fraction. At present, the understanding of heart failure with mildly reduced ejection fraction is still in its infancy. There is a lack of large-scale prospective randomized controlled trials for patients with mildly reduced ejection fraction, and the evidence-based medical evidence for its treatment and prognosis is limited. Heart failure with preserved ejection fraction (left ventricular ejection fraction>50%) accounts for a large proportion of heart failure patients and is characterized by abnormal left ventricular diastolic function. Although the mortality rate of heart failure with preserved ejection fraction is similar to that of heart failure with reduced ejection fraction, the pathogenic mechanisms of the two are different, and there is no evidence-based medical evidence to prove that drugs are effective for heart failure with preserved ejection fraction.

[0006] Although there is no name for heart failure in ancient Chinese medical books, it is classified into the categories of "heart paralysis", "heart swelling", "asthma", "heart water" and so on according to its clinical manifestations. Modern Chinese medicine believes that the basic pathogenesis of heart failure is the deficiency of heart qi, and qi deficiency and blood stasis are throughout. The imbalance of yin and yang is the basis of pathological evolution, and phlegm, fluid retention and water retention are its final product. Traditional Chinese medicine believes that qi is the commander of blood, and blood flows when qi moves. The normal flow of blood depends on the promotion of heart qi. When the heart qi is full, the blood circulates normally. If the heart qi is deficient and the agitation is weak, the blood will not flow smoothly and the blood vessels will be blocked. Therefore, clinical symptoms such as chest tightness and pain, palpitations, dark complexion, purple lips and nails, petechiae and ecchymosis on the tongue, lumps under the ribs, and distended neck veins can be seen.

[0007] Currently, there is no Chinese herbal compound specifically for the treatment of heart failure. Therefore, the market urgently needs to develop a Chinese herbal medicine that has precise and significant efficacy, sophisticated technology, and stable drug quality for the targeted treatment of heart failure or heart failure. Summary of the invention

[0008] One or more embodiments of the present application provide a Chinese medicine composition for treating and / or preventing heart failure or heart insufficiency, wherein the Chinese medicine composition is prepared from the following medicinal materials in parts by weight: 1-2 parts of ginseng, 1-2 parts of salvia miltiorrhiza, and 6-8 parts of Corydalis yanhusuo.

[0009] In one or more embodiments, the traditional Chinese medicine composition is prepared from the following medicinal materials in parts by weight: 1.7 parts of ginseng, 1 part of salvia miltiorrhiza, and 6.9 parts of Corydalis yanhusuo.

[0010] In one or more embodiments, the Chinese medicine composition is prepared by the following method: extracting ginseng, salvia miltiorrhiza, and Corydalis yanhusuo with ethanol or ethanol-water solution respectively, mixing the obtained ginseng extract, salvia miltiorrhiza extract, and Corydalis yanhusuo extract to obtain the Chinese medicine composition.

[0011] In one or more embodiments, the ethanol aqueous solution is 60 volume % to 70 volume % ethanol aqueous solution.

[0012] In one or more embodiments, the traditional Chinese medicine composition is prepared by the following method: extracting ginseng, salvia miltiorrhiza, and Corydalis yanhusuo with ethanol or ethanol aqueous solution, respectively, purifying the ginseng extract, salvia miltiorrhiza extract, and Corydalis yanhusuo extract with resin, and mixing the obtained ginseng extract, salvia miltiorrhiza extract, and Corydalis yanhusuo extract to obtain the traditional Chinese medicine composition.

[0013] In one or more embodiments, the resin is a macroporous adsorption resin.

[0014] In one or more embodiments, the ginseng extract is purified using AB-8 macroporous adsorption resin, the salvia miltiorrhiza extract is purified using KLY-134 macroporous adsorption resin, and the Corydalis yanhusuo extract is purified using AB-8 macroporous adsorption resin.

[0015] In one or more embodiments, the purification is performed by eluting with water to remove impurities, and collecting the ethanol elution portion.

[0016] In one or more embodiments, the Chinese medicine composition is prepared by the following method: taking ginseng, refluxing with 60% ethanol to obtain an extract, concentrating under reduced pressure, purifying the concentrate with an AB-8 macroporous pore, eluting with water, and then eluting with 10% ethanol, discarding the water and 10% ethanol eluate, continuing to elute with 70% ethanol, collecting the 70% ethanol eluate to obtain a ginseng extract; taking salvia miltiorrhiza, refluxing with 60% ethanol to obtain an extract, concentrating under reduced pressure, and purifying the concentrate with a KLY-134 macroporous pore. The extract was purified by a macroporous adsorption resin, eluted with water, and then eluted with 60% ethanol, the water eluate was discarded, and the 60% ethanol eluate was collected to obtain a Salvia miltiorrhiza extract; Corydalis yanhusuo was extracted with 70% ethanol to obtain an extract, and the extract was concentrated under reduced pressure, and the concentrate was purified by an AB-8 macroporous adsorption resin, eluted with water, and then eluted with 80% ethanol, the water eluate was discarded, and the 80% ethanol eluate was collected to obtain a Corydalis yanhusuo extract; the ginseng extract, Salvia miltiorrhiza extract, and Corydalis yanhusuo extract were combined to obtain the traditional Chinese medicine composition.

[0017] One or more embodiments of the present application provide a pharmaceutical preparation, which comprises the Chinese medicine composition of the present application and a pharmaceutically acceptable carrier, adjuvant or excipient.

[0018] In one or more embodiments, the pharmaceutical preparation further comprises other drugs for treating and / or preventing heart dysfunction or heart failure.

[0019] In one or more embodiments, the pharmaceutical preparation is a granule, a tablet, a powder or a capsule.

[0020] One or more embodiments of the present application provide the use of a traditional Chinese medicine composition in the preparation of a medicament for treating and / or preventing heart failure, wherein the traditional Chinese medicine composition is prepared from the following medicinal materials in parts by weight: 1-30 parts of ginseng, 1-15 parts of salvia miltiorrhiza, and 15-80 parts of Corydalis yanhusuo.

[0021] In one or more embodiments, the traditional Chinese medicine composition is prepared from the following medicinal materials in parts by weight: 1-20 parts of ginseng, 1-10 parts of salvia miltiorrhiza, and 20-50 parts of Corydalis yanhusuo.

[0022] In one or more embodiments, the traditional Chinese medicine composition is prepared from the following medicinal materials in parts by weight: 1-2 parts of ginseng, 1-2 parts of salvia miltiorrhiza, and 6-8 parts of Corydalis yanhusuo.

[0023] In one or more embodiments, the traditional Chinese medicine composition is prepared from the following medicinal materials in parts by weight: 1.7 parts of ginseng, 1 part of salvia miltiorrhiza, and 6.9 parts of Corydalis yanhusuo.

[0024] In one or more embodiments, the Chinese medicine composition is prepared by the following method: extracting ginseng, salvia miltiorrhiza, and Corydalis yanhusuo with ethanol or ethanol-water solution respectively, mixing the obtained ginseng extract, salvia miltiorrhiza extract, and Corydalis yanhusuo extract to obtain the Chinese medicine composition.

[0025] In one or more embodiments, the ethanol aqueous solution is 60 volume % to 70 volume % ethanol aqueous solution.

[0026] In one or more embodiments, the traditional Chinese medicine composition is prepared by the following method: extracting ginseng, salvia miltiorrhiza, and Corydalis yanhusuo with ethanol or ethanol aqueous solution, respectively, purifying the ginseng extract, salvia miltiorrhiza extract, and Corydalis yanhusuo extract with resin, and mixing the obtained ginseng extract, salvia miltiorrhiza extract, and Corydalis yanhusuo extract to obtain the traditional Chinese medicine composition.

[0027] In one or more embodiments, the resin is a macroporous adsorption resin.

[0028] In one or more embodiments, the ginseng extract is purified using AB-8 macroporous adsorption resin, the salvia miltiorrhiza extract is purified using KLY-134 macroporous adsorption resin, and the Corydalis yanhusuo extract is purified using AB-8 macroporous adsorption resin.

[0029] In one or more embodiments, the purification is performed by eluting with water to remove impurities, and collecting the ethanol elution portion.

[0030] In one or more embodiments, the Chinese medicine composition is prepared by the following method:

[0031] Take ginseng, extract with 60% ethanol by refluxing to obtain an extract, concentrate under reduced pressure, purify the concentrate with AB-8 macropore, elute with water, then elute with 10% ethanol, discard the eluate with water and 10% ethanol, continue to elute with 70% ethanol, collect the eluate with 70% ethanol, and obtain ginseng extract;

[0032] Take Danshen, extract with 60% ethanol by refluxing to obtain an extract, concentrate under reduced pressure, purify the concentrate with KLY-134 macroporous adsorption resin, elute with water, and then elute with 60% ethanol, discard the water eluate, collect the 60% ethanol eluate, and obtain Danshen extract;

[0033] Take Corydalis yanhusuo, extract with 70% ethanol under reflux to obtain an extract, concentrate under reduced pressure, purify the concentrate with AB-8 macroporous adsorption resin, elute with water, then elute with 80% ethanol, discard the water eluate, collect the 80% ethanol eluate, and obtain the Corydalis yanhusuo extract;

[0034] The ginseng extract, salvia miltiorrhiza extract and Corydalis yanhusuo extract are combined to obtain the traditional Chinese medicine composition.

[0035] In one or more embodiments, the cardiac insufficiency is caused by myocardial dystrophy.

[0036] In one or more embodiments, the myocardial dystrophy is caused by myocardial energy metabolism disorder or myocardial microcirculation disorder.

[0037] In one or more embodiments, the heart failure is chronic or acute heart failure.

[0038] In one or more embodiments, the heart failure is chronic heart failure.

[0039] In one or more embodiments, the heart failure is heart failure with reduced ejection fraction.

[0040] In one or more embodiments, the heart failure with reduced ejection fraction is heart failure with a left ventricular ejection fraction of <40%.

[0041] In one or more embodiments, the Chinese medicine composition prepared from ginseng, salvia miltiorrhiza and Corydalis yanhusuo of the present application has the effects of invigorating qi and promoting blood circulation, removing blood stasis and relieving pain, and can be used for and / or treating chest pain caused by qi deficiency and blood stasis, with symptoms of chest pain, chest tightness, shortness of breath, palpitations, fatigue, dark purple lips, pale and dark tongue, weak and astringent pulse; angina pectoris caused by coronary heart disease, heart failure, microvascular angina pectoris and perioperative treatment of percutaneous coronary intervention.

[0042] In one or more embodiments, the Chinese medicine composition of the present application complies with the theory of traditional Chinese medicine, and the extracted and refined preparations have been proven to be definite in efficacy, safe and effective in animal experiments.

[0043] In one or more embodiments, the Chinese medicine composition of the present application establishes a systematic treatment prescription for heart failure, focusing on the prevention and treatment of heart failure, with a wide range of raw materials, no toxic side effects, a reasonable prescription, and good efficacy.

[0044] In one or more embodiments, the Chinese medicine composition of the present application can treat coronary microcirculation disorders.

[0045] In one or more embodiments, the Chinese medicine composition further comprises pharmaceutically acceptable excipients, and the above-mentioned pharmaceutical preparation can be in any dosage form, such as granules, tablets, powders, and capsules.

[0046] Ginseng is the dried root of Panax ginseng CAMey. of the Araliaceae family.

[0047] Salvia miltiorrhiza is the dried root and rhizome of Salvia miltiorrhiza Bunge., a plant of the Lamiaceae family.

[0048] Corydalis yanhusuo is the dried tuber of Corydalis yanhusuo WTWW, a plant of the Poppy family.

[0049] In one or more embodiments, the heart failure treated by the Chinese medicine composition of the present application is more common in the syndrome of qi deficiency and blood stasis in coronary heart disease, and the method of invigorating qi and activating blood circulation, removing blood stasis and promoting qi circulation to relieve pain has a good effect on it. Ginseng is used in the prescription to greatly replenish the vital energy, invigorate qi and activate blood circulation, make qi prosperous and blood circulation, remove blood stasis and unblock the collaterals, and is the main medicine. Salvia miltiorrhiza is used as the main medicine for promoting blood circulation and removing blood stasis. It tastes bitter and slightly cold, and it can promote blood circulation, remove blood stasis and relieve pain without hurting qi and blood. Corydalis yanhusuo is pungent, dispersing, warming and unblocking, "can promote qi stagnation in the blood, blood stasis in the qi, and treat pain from top to bottom of the body" to relieve pain. The whole prescription has only three flavors, and the medicinal properties are mild, taking into account the symptoms and the root cause, treating qi and blood at the same time, and focusing on invigorating qi, so that qi is prosperous and blood circulation is stasis-removing and pain stops. Play the role of invigorating qi, activating blood circulation and relieving pain. All the above medicines are included in the "Pharmacopoeia of the People's Republic of China (2020 Edition)". BRIEF DESCRIPTION OF THE DRAWINGS

[0050] Figure 1The ultrasonic images of the hearts of rats in each group are shown, wherein A, sham operation group; B, model group; C, valsartan group; D-F: groups of the Chinese medicine composition of the present application at 180, 90, and 45 mg / kg.

[0051] Figure 2 Represents the TTC staining images of the hearts of rats in each group, where A, sham operation group; B, model group; C, valsartan group;

[0052] D~F: 180, 90, 45 mg / kg groups of the Chinese medicine composition of the present application.

[0053] Figure 3 The figures represent HE staining of myocardial tissues of rats in each group (×200), wherein A, sham operation group; B, model group; C, valsartan group; D-F: groups treated with the Chinese medicine composition of the present application at 180, 90, and 45 mg / kg.

[0054] Figure 4 The Masson staining (×200) of the myocardial tissues of rats in each group, wherein A, sham operation group; B, model group; C, valsartan group; D-F: groups treated with the Chinese medicine composition of the present application at 180, 90, and 45 mg / kg.

[0055] Figure 5 Represents cardiac ultrasound images of rats in each group, wherein A, sham operation group; B, model group; C, 90 mg / kg group of the Chinese medicine composition of the present application; D, 45 mg / kg group of the Chinese medicine composition of the present application; E, Nicorandil group; F, Tongxinluo capsule group.

[0056] Figure 6 Represents the cardiac function indexes of rats in each group, where A, sham operation group; B, model group; C, 90 mg / kg group of the Chinese medicine composition of the present application; D, 45 mg / kg group of the Chinese medicine composition of the present application; E, Nicorandil group; F, Tongxinluo capsule group. EF, ejection fraction; FS, fractional shortening; SV, stroke volume; CO, cardiac output; LAVWs, left ventricular anterior wall systolic thickness; LVAWd, left ventricular anterior wall diastolic thickness. Compared with the sham operation group, # P<0.05, ## P<0.01; compared with the model group, * P<0.05, ** P<0.01.

[0057] Figure 7 The images represent the peak time of myocardial blood perfusion in rats of each group, wherein A, sham operation group; B, model group; C, 90 mg / kg group of the Chinese medicine composition of the present application; D, 45 mg / kg group of the Chinese medicine composition of the present application; E, Nicorandil group; F, Tongxinluo capsule group.

[0058] Figure 8The graph shows the peak time of myocardial blood perfusion in each group of rats, where A is the sham operation group; B is the model group; C is the 90 mg / kg group of the Chinese medicine composition of the present application; D is the 45 mg / kg group of the Chinese medicine composition of the present application; E is the Nicorandil group; and F is the Tongxinluo capsule group. Compared with the sham operation group, # P<0.05, ## P<0.01; compared with the model group, * P<0.05, ** P<0.01.

[0059] Fig. 9 The myocardial infarction diagrams and statistical diagrams of rats in each group are shown, among which A is the sham operation group; B is the model group; C is the 90 mg / kg group of the Chinese medicine composition of the present application; D is the 45 mg / kg group of the Chinese medicine composition of the present application; E is the Nicorandil group; F is the Tongxinluo capsule group. Taking the model group as an example (indicated by the red arrow), the yellow circle is the ischemic area, and the red circle is the infarction area. Compared with the sham operation group, # P<0.05, ## P<0.01; compared with the model group, * P<0.05, ** P<0.01.

[0060] Fig.10 The graphs and statistical graphs of myocardial no-reflow area in each group of rats are shown, where A is the sham operation group; B is the model group; C is the 90 mg / kg group of the Chinese medicine composition of the present application; D is the 45 mg / kg group of the Chinese medicine composition of the present application; E is the Nicorandil group; and F is the Tongxinluo capsule group. The red arrow points to the no-reflow area. Compared with the sham operation group, # P<0.05, ## P<0.01; compared with the model group, * P<0.05, ** P<0.01.

[0061] Fig.11 The statistical graphs of serum LDH, CK, and CK-MB of rats in each group are shown, among which A is the sham operation group; B is the model group; C is the 90 mg / kg group of the Chinese medicine composition of the present application; D is the 45 mg / kg group of the Chinese medicine composition of the present application; E is the Nicorandil group; and F is the Tongxinluo capsule group. Compared with the sham operation group, # P<0.05, ## P<0.01; compared with the model group, * P<0.05, ** P<0.01.

[0062] Fig.12The statistical graphs of serum cAMP, cGMP, ATP, ADP, and AMP of rats in each group are shown, where Sham is the sham operation group; Model is the model group; SSNX is the 90 mg / kg group of the Chinese medicine composition of the present application. Compared with the sham operation group, # P<0.05, ## P<0.01; compared with the model group, * P<0.05, ** P<0.01.

[0063] Fig.13 The diagrams show the energy metabolism-related indicators of myocardial cells in each group of rats, including A, energy distribution diagram of AMP, ADP, ATP, GMP, GDP and GTP; B, bar graph of AMP, ADP, ATP, GMP, GDP and GTP. C, energy change formula of myocardial tissue. The area indicated by the blue arrow in the HE diagram turns white and light, belonging to the ischemic infarction area. Compared with the sham operation group, # P<0.05, ## P<0.01; compared with the model group, * P<0.05, ** P<0.01. Example

[0064] Preparation Example

[0065] Prescription: 827g ginseng, 480g salvia miltiorrhiza, 3333g Corydalis yanhusuo, and appropriate amounts of auxiliary materials such as micro-powder silica gel and dextrin.

[0066] Preparation method:

[0067] Take ginseng slices, add 60% ethanol in an amount (ml) 8 times the weight (g) of ginseng, reflux extraction 3 times, 3 hours each time, combine the extracts, concentrate under reduced pressure to a relative density of 1.05 (50°C), add distilled water in an amount (ml) 2 times the weight (g) of ginseng to the concentrate, filter, adsorb the filtrate with AB-8 type macroporous adsorption resin, elute the drug-loaded resin with 2BV column volumes of water, continue to elute the drug-loaded resin with 1.5BV column volumes of 10% ethanol, discard the water and 10% ethanol eluate, continue to elute the drug-loaded resin with 2.5 column volumes of 70% ethanol, collect the 70% ethanol eluate, concentrate under reduced pressure, and vacuum dry to obtain ginseng extract.

[0068] Take Danshen decoction pieces, add 60% ethanol in an amount of 6 times (ml) of Danshen weight (g), reflux extraction 3 times, each time for 1.5 hours, combine the extracts, recover ethanol under reduced pressure until there is no alcohol taste, add water to a relative density of 1.030 (room temperature), adsorb the water suspension through KLY-134 macroporous adsorption resin, the resin diameter-to-height ratio is 1:6, the sample loading is 5BV, wash and remove impurities with 1BV of water, and elute with 60% ethanol with a volume of 3BV, the flow rate is 0.5-1BV / h. Collect the ethanol elution part, recover the ethanol, and dry under reduced pressure to obtain Danshen extract.

[0069] Take the Corydalis yanhusuo slices, add 70% ethanol in an amount (ml) 8 times the weight (g) of Corydalis yanhusuo, reflux extract 3 times, 2 hours each time, combine the extracts, recover ethanol under reduced pressure until there is no alcohol taste, add water to a relative density of 1.022 (room temperature), adsorb the water suspension through AB-8 type macroporous adsorption resin, the sample flow rate is 0.5-1BV / h, the diameter-to-height ratio is 1:8, the sample load is 5BV, and the impurities are removed by elution with a volume of 2BV of water, the flow rate is 0.5-1BV / h, and the elution is eluted with 80% ethanol, the elution flow rate is 3BV / h, and the elution volume is 8BV. Collect the ethanol elution part, recover the ethanol, and dry under reduced pressure to obtain the Corydalis yanhusuo extract.

[0070] The above three extracts are crushed into 80 meshes respectively, mixed, added with appropriate amount of micro powder silica gel and dextrin, made into soft material, granulated, dried, and filled into capsules to obtain the product.

[0071] Active Example 1

[0072] In the active examples, the effects of the Chinese medicine composition of the present application on rats with heart failure were studied, and the protective effect of the Chinese medicine composition of the present application on the hearts of rats with heart failure was explored.

[0073] Methods: The rat heart failure model was established by ligating the anterior descending coronary artery. The cardiac function of the rats was examined by color Doppler ultrasound. The levels of plasma BNP, ANP and AngII were measured by ELISA kit. The activities of serum CK, CK-MB and LDH were determined by automatic biochemical analyzer. The myocardial infarction area was observed by TTC staining. The changes of myocardial tissue morphology were observed by HE and Masson staining.

[0074] Results: Compared with the model group, the Chinese medicine composition of the present application can significantly improve the cardiac function of rats with heart failure, increase LVAWs, LVPWs, LVPWd, SV, CO, EF and FS, and reduce LVIDs, LVIDd, LVVs and LVVd; reduce serum CK, CK-MB and LDH activities, reduce BNP, ANP, AngII levels, reduce myocardial infarction area, and reduce ischemic changes and fibrosis of myocardial tissue.

[0075] Conclusion: The Chinese medicine composition of the present application can improve myocardial damage in rats with heart failure after myocardial infarction, inhibit fibrosis, slow down the development of heart failure, and thus improve cardiac function.

[0076] 1. Materials

[0077] 1.1 Experimental animals

[0078] Male SD rats, weighing 240-260 g, were purchased from Sibeifu (Beijing) Biotechnology Co., Ltd. Animal license: SCXK (Beijing) 2019-0010. Animal breeding and experimental operations were carried out in the Experimental Animal Center of Xiyuan Hospital, China Academy of Chinese Medical Sciences [SYXK (Beijing) 2018-0018]. The handling of experimental animals strictly followed the 3R principle of "reduction, replacement, and optimization" and provided humanitarian care.

[0079] 1.2 Drugs and reagents

[0080] The Chinese medicine composition of the present application is prepared according to the above preparation example, and is provided by the Pharmacy Department of the Institute of Basic Medicine, Xiyuan Hospital, China Academy of Chinese Medical Sciences, batch number: 20180714; valsartan, Tianda Pharmaceutical (Zhuhai) Co., Ltd., specification 80 mg / tablet, batch number 3220704; sodium pentobarbital, imported from Germany, Beijing Chemical Reagent Company, batch number: 020402. Creatine kinase (CK) assay kit, creatine kinase MB isoenzyme (CK-MB) assay kit, lactate dehydrogenase (LDH) assay kit are all products of Fujifilm and Guang Chunyao (Shanghai) Chemical Co., Ltd., batch numbers: 220328, 204837, 205884 respectively; rat brain natriuretic peptide (BNP) kit, rat atrial peptide (ANP) kit, rat angiotensin II (AngII) kit, provided by Ains Biological Company, batch numbers INS-30639, INS-30882, INS-31165 respectively.

[0081] 1.3 Experimental instruments

[0082] Dual-channel small animal ventilator, Beijing Yinuotai Biological Development Co., Ltd.; Baiyang BY-R16 high-speed refrigerated centrifuge, Beijing Baiyang Medical Equipment Co., Ltd.; LABOSPECT003 fully automatic biochemical analyzer, Hitachi, Japan; MPIAS-500 multimedia color pathology graphic analysis system, Beijing Zhengheng Bocheng Technology Development Co., Ltd.

[0083] 2. Methods

[0084] 2.1 Experimental groups and drug administration

[0085] The experimental animals were randomly divided into 6 groups, with 15 animals in each group. The groups were as follows: (1) sham operation group (Sham); (2) model control group (Model); (3) positive drug control group (valsartan); (4) 180 mg / kg group of the Chinese medicine composition of the present application; (5) 90 mg / kg group of the Chinese medicine composition of the present application; (6) 45 mg / kg group of the Chinese medicine composition of the present application. The valsartan group was converted to an equivalent dose according to the literature, and the dose was 10 mg / kg, which is equivalent to the equivalent dose used in clinical adults. After the rat myocardial infarction model surgery, the sham operation group and the model group were gavaged with normal saline for 14 days, and the other groups were continuously gavaged for 14 days, and each group was gavaged at 1 mL / 100 g body weight.

[0086] 2.2 Preparation of rat heart failure model

[0087] Rats were anesthetized intraperitoneally with 0.3% sodium pentobarbital solution at a dose of 1 mL / 100 g. After the righting reflex of the rat disappeared, the limbs and head were fixed on the surgical board in the supine position. A handheld hair remover was used to remove hair on the left chest and limbs. The rat was intubated and mechanically respired using a ventilator. The skin between the 3rd and 4th ribs on the left side of the rat's sternum was longitudinally cut open, the muscle tissue was bluntly separated with hemostats, the exposed ribs were cut off with surgical scissors, the chest cavity was opened with a thoracotomy device, the pericardium was gently separated, the heart and the left anterior descending branch were fully exposed, and the No. 0 surgical thread was threaded about 2 mm away from the bifurcation of the left anterior descending branch of the rat. The distal ventricular muscle of the heart was observed to turn from red to pale, and the ST segment of the electrocardiogram was observed to be arched upward, indicating that the myocardial infarction model was successfully prepared. The respiratory state of the rat was closely observed. When the rat recovered spontaneous breathing, a cotton swab was dipped in penicillin to disinfect the muscle, the chest cavity was sutured, and the rat was returned to the breeding box after autonomous activity. The sham control group only threaded the thread without ligation, and the rest of the steps were the same as above. The rats were fed for 14 days after surgery to establish a heart failure model.

[0088] 2.3 Echocardiography to detect cardiac function

[0089] 14 days after surgery, the rats were anesthetized and the left anterior chest area was extensively prepared. The rats were fixed in the supine position. When the rats' heart rhythm tended to be continuous and stable, the detection began. During the echocardiography examination, the respiratory state of the rats should be observed. If obvious respiratory depression occurred, the examination should be terminated and respiratory support should be performed. The high-frequency probe was used for positioning, and the M-mode echocardiography was used to observe the cardiac motion in the left ventricular long axis and parasternal short axis sections. The left ventricular long axis section was selected to calculate the left ventricular end-diastolic and end-systolic posterior wall thickness (LVPWd and LVPWs), the left ventricular anterior wall thickness (LVAWd and LVAWs) at end-diastolic and end-systolic, the left ventricular end-diastolic and end-systolic internal diameter (LVIDd and LVIDs), the left ventricular end-diastolic and end-systolic volume (LVVd and LVVs), the stroke volume (SV), the cardiac output (CO), the left ventricular ejection fraction (LVEF), the left ventricular shortening fraction (LVFS) and other indicators.

[0090] 2.4 Serum CK, CK-MB and LDH activity determination

[0091] Fourteen days after surgery, blood was collected from the abdominal aorta of the rats. After standing at room temperature for 1 hour, the blood was centrifuged at 2500 rpm for 10 minutes. The supernatant was collected and the activities of CK, CK-MB and LDH were detected by biochemical analysis.

[0092] 2.5 Determination of serum BNP and AngII levels

[0093] 14 days after surgery, blood was collected from the abdominal aorta of the rats, and after standing at room temperature for 1 hour, the blood was centrifuged at 2500 rpm for 10 minutes. The supernatant was collected and tested by ELISA. The specific operation was carried out according to the instructions of the kit.

[0094] 2.6 HE staining of rat myocardial tissue

[0095] After the experiment, the rats in each group were anesthetized, the left ribs were cut open, the hearts were exposed and removed, and the left ventricular mid-section was removed through a cross-section at the distal 1 / 3 of the heart under the cardiac ligature, and fixed in 4% paraformaldehyde solution. The pathological changes of ischemic myocardial tissue were observed under a light microscope.

[0096] 2.7 Masson staining of rat myocardial tissue

[0097] Dewax the paraffin sections to water, immerse the sections in Masson A solution overnight, wash with tap water, and then immerse in a dye solution mixed with Masson B solution and Masson C solution in equal proportions for 1 minute, differentiate with 1% hydrochloric acid alcohol. Then immerse the sections in Maason D solution for 6 minutes, wash with tap water, and then immerse in Masson E and F solutions. After rinsing, differentiation, and dehydration, the sections are transparently sealed and examined under a microscope.

[0098] 2.8 Statistical analysis

[0099] The experimental data were statistically analyzed using SPSS16.0 software. The experimental data of each group were expressed as mean±standard deviation (±s) after passing the homogeneity of variance test. One-way ANOVA was used for comparison among multiple groups; two independent sample t-test (T-Test) was used for pairwise comparison. P<0.05 was considered statistically significant.

[0100] 3. Results

[0101] 3.1 Effects on echocardiographic parameters in rats

[0102] Compared with the sham operation group, the LVAWs, LVAWd, and LVPWs of the rats in the model group were significantly reduced (P < 0.01); at the same time, LVIDSs, LVIDd, LVVs, and LVVd were significantly increased (P < 0.01). In addition, the SV, CO, EF, FS, and of the rats in the model group were also significantly reduced compared with those in the sham operation group (P < 0.01). Compared with the model group, the LVPWs, EF, and FS of the valsartan group were significantly increased (P < 0.01), and LVIDs, LVIDd, and LVVs were significantly decreased (P < 0.01). Compared with the model group, the LVAWs, LVPWs, LVPWd, SV, CO, EF, and FS of the 180 mg / kg group of the Chinese medicine composition of the present application were significantly increased (P < 0.05, P < 0.01), and LVIDs, LVIDd, LVVs, and LVVd were significantly decreased (P < 0.01). Compared with the model group, the LVAWs, LVPWs, LVPWs, LVPWd, SV, CO, EF and FS of the 90 mg / kg group of the Chinese medicine composition of the present application were significantly increased (P < 0.05, P < 0.01), and the LVIDs, LVIDd, LVVs and LVVd were significantly decreased (P < 0.01). Compared with the model group, the LVAWs, LVPWs, LVPWs, LVPWd, EF and FS of the 45 mg / kg group of the Chinese medicine composition of the present application were significantly increased (P < 0.05, P < 0.01), and the LVIDs, LVIDd, LVVs and LVVd were significantly decreased (P < 0.01). The results are shown in Figure 1 , Table 1.

[0103] Table 1. Comparison of echocardiographic parameters of rat hearts in each group (±s, n=14-15)

[0104]

[0105] Note: Compared with the sham operation group, * P<0.05, ** P<0.01; compared with the model group, #P<0.05, ## P<0.01.

[0106] 3.2 Effects on serum myocardial enzymes in rats

[0107] Compared with the sham operation group, the activities of serum CK, LDH and CK-MB in the model group were significantly increased (P < 0.01). Compared with the model group, the activities of serum CK, LDH and CK-MB in the valsartan group were significantly decreased (P < 0.01). Compared with the model group, the activities of serum CK, LDH and CK-MB in the animals in each dose group of the Chinese medicine composition of the present application were significantly decreased (P < 0.05, P < 0.01). See Table 2.

[0108] Table 2. Comparison of serum CK, LDH and CK-MB activities in rats of each group (±s)

[0109]

[0110] Note: Compared with the sham operation group, * P<0.05, ** P<0.01; compared with the model group, # P<0.05, ## P<0.01.

[0111] 3.3 Effects on serum BNP, ANP and AngII in rats

[0112] Compared with the sham operation group, the serum BNP, ANP and AngII levels of the rats in the model group were significantly increased. (P < 0.01). Compared with the model group, the serum BNP, ANP and AngII of the valsartan group were significantly reduced (P < 0.01). Compared with the model group, the serum BNP of the animals in each dose group of the Chinese medicine composition of the present application showed a downward trend, among which the 180 mg / kg group of the Chinese medicine composition of the present application and the 90 mg / kg group of the Chinese medicine composition of the present application showed significant differences compared with the model group (P < 0.01). Compared with the model group, the serum ANP and AngII of the animals in each dose group of the Chinese medicine composition of the present application showed a downward trend, among which the 180 mg / kg group of the Chinese medicine composition of the present application showed significant differences compared with the model group (P < 0.01). See Table 3.

[0113] Table 3. Comparison of serum BNP, ANP and AngII in rats of each group (±s)

[0114]

[0115] Note: Compared with the sham operation group, * P<0.05, ** P<0.01; compared with the model group, # P<0.05, ## P<0.01.

[0116] 3.4 Effect on myocardial infarction area in rats

[0117] Compared with the model group, the myocardial infarction area rate in the valsartan group and each dosage group of the Chinese medicine composition of the present application was significantly reduced (P<0.05, P<0.01). See Table 4.

[0118] Table 4. Comparison of myocardial infarction area rate in rats of each group (±s)

[0119]

[0120] Note: Compared with the model group, # P<0.05, ## P<0.01.

[0121] 3.5 Effects on the pathological structure of rat myocardial tissue

[0122] Under the light microscope, the three-layer structure of the heart wall of rats in the sham operation group was clear and normal in proportion; the myocardial fibers were arranged neatly, orderly and tightly, and myocardial cells did not show degeneration or necrosis; there was no fibrous tissue hyperplasia in the interstitium, no vascular hyperplasia or edema, and no obvious inflammatory cell infiltration. The myometrium was slightly thickened, and the adventitia was significantly thickened; the myocardial fibers were arranged loosely and disorderly, with widened intervals, and myocardial cell edema and degeneration were obvious, and small pieces of necrosis were visible; there was focal fibrous tissue hyperplasia in the interstitium, vascular hyperplasia and dilation, large blood vessels were remodeled, edema was obvious, hemosiderin deposition was visible locally, and a large number of lymphocytes, macrophages, and mast cells were infiltrated. In the valsartan group, the myometrium and adventitia of the heart were not obviously thickened; the local myocardial fibers were arranged slightly loosely and disorderly, with widened intervals, and myocardial cells were moderately edematous and degenerated, with punctate necrosis; there was no obvious hyperplasia of fibrous tissue in the interstitium, a small number of blood vessels were hyperplastic and dilated, vascular remodeling and edema were reduced, and the number of infiltrating lymphocytes, macrophages, and mast cells decreased.

[0123] In the rat cardiac myometrium and adventitia thickening was not obvious in each dose group of the Chinese medicine composition of the present application; the local myocardial fibers were slightly loose and disordered, the intervals were slightly widened, the focal myocardial cells were edematous and degenerated, and punctate necrosis was seen; the interstitial fibrous tissue proliferation was not obvious, the blood vessels were slightly proliferated and dilated, the large blood vessels were remodeled, there was mild edema, and moderate lymphocytes, macrophages, and mast cells were infiltrated. Among them, the high-dose and medium-dose groups had better effects. Figure 3 .

[0124] After Masson staining of myocardial tissue, small, scattered myocardial tissue fibrosis was observed in the sham operation group. Compared with the sham operation group, the rats in the model group showed obvious myocardial tissue fibrosis. Compared with the model group, the degree of myocardial tissue fibrosis in the valsartan group and the various dose groups of the Chinese medicine composition of the present application was significantly reduced. Figure 4 .

[0125] 4. Discussion and Results

[0126] Heart failure is the terminal stage of many cardiovascular diseases and poses a serious threat to human health. Myocardial remodeling is the main determinant of heart failure morbidity and mortality and a key link in the progression of heart failure. Currently, the main treatments for heart failure include controlling heart failure risk factors, drug therapy, interventional therapy, and heart transplantation. All of the above methods can improve patients' clinical symptoms and delay the progression of heart failure, but these methods cannot fundamentally improve myocardial remodeling and prevent the occurrence of heart failure.

[0127] The present application successfully established an animal model of ischemic heart failure in rats by ligating the left anterior descending branch of the coronary artery, and observed the improvement effect of the present application composition on ischemic heart failure. The results show that the present application Chinese medicine composition can significantly improve the cardiac function of rats with heart failure, reduce the level of myocardial enzymes in myocardial injury, reduce the area of ​​myocardial infarction, inhibit rat ventricular remodeling, improve cardiac function and heart failure biomarkers, and by reducing the level of angiotensin II, block the activation of the renin-angiotensin-aldosterone system in the pathological process of heart failure, and achieve the effect of reducing the development of heart failure and improving cardiac function. It can be seen from this that the present application Chinese medicine composition has a good therapeutic effect on heart failure and has a good value for clinical application.

[0128] Active Example 2

[0129] In the active examples, the effects of the Chinese medicine composition of the present application on rats with heart failure were studied, and the protective effect of the Chinese medicine composition of the present application on the hearts of rats with heart failure was explored.

[0130] Methods: Myocardial ischemia-reperfusion / injury (MIRI) was used to induce a rat heart failure model. Color Doppler ultrasound was used to examine the cardiac function and myocardial perfusion of the rats. ELISA kits were used to examine the activities of CK, CK-MB and LDH as well as the levels of cAMP, cGMP, ATP, ADP and AMP in the rats. TTC staining was used to observe the myocardial infarction area, thioflavin-s staining was used to observe the no-reflow area, and mass spectrometry imaging was used to observe the changes in molecules related to myocardial energy metabolism.

[0131] Results: Compared with the model group, the Chinese medicine composition of the present application can significantly improve the cardiac function of rats with heart failure, increase EF, FS and LVAWs, CO, SV and LVAWd; reduce serum CK, CK-MB and LDH activities, reduce BNP, ANP, AngII content, reduce myocardial infarction area, reduce ischemic changes and fibrosis of myocardial tissue. Increase the serum cAMP, AMP, ATP content of rats, reduce serum cGMP, ADP content; increase myocardial ATP production, AMP content, reduce energy charge, and show a low energy charge state compared with the model group, and increase ATP production.

[0132] Conclusion: The Chinese medicine composition of the present application can improve myocardial energy metabolism, increase ATP production, and play a protective role against heart failure by improving the decreased cardiac function of MIRI rats.

[0133] 1. Materials

[0134] 1.1 Experimental animals

[0135] Male SD rats, weight 220 ± 20 g, Beijing Weitonglihua Experimental Animal Technology Co., Ltd., animal license number SCXK (Beijing) 2021-0006. Animal breeding and experimental operations were carried out in the Experimental Animal Center of Xiyuan Hospital, China Academy of Chinese Medical Sciences [SYXK (Beijing) 2018-0018]. The handling of experimental animals strictly followed the 3R principle of "reduction, replacement, and optimization" and provided humanitarian care.

[0136] 1.2 Drugs and reagents

[0137] The Chinese medicine composition of the present application is prepared according to the above preparation example, and is provided by the Pharmacy Department of the Institute of Basic Medicine, Xiyuan Hospital, China Academy of Chinese Medical Sciences, batch number: 20180714; Tongxinluo Capsules, Shijiazhuang Yiling Pharmaceutical Co., Ltd., batch number A2102056; Pentobarbital sodium, imported from Germany, Beijing Chemical Reagent Company, batch number: 020402. Creatine kinase (CK) assay kit, creatine kinase MB isoenzyme (CK-MB) assay kit, lactate dehydrogenase (LDH) assay kit are all products of MacBio Co., Ltd., batch numbers: 210203, 101363, 103424 respectively. cAMP, cGMP, ATP, AMP, ADP kits are all products of Ains Bio, batch numbers: J30440, J30439, J30726, J30967, J30341 and J30967 respectively.

[0138] 1.3 Experimental instruments

[0139] Dual-channel small animal ventilator, Beijing Yinuotai Biological Development Co., Ltd.; Baiyang BY-R16 high-speed refrigerated centrifuge, Beijing Baiyang Medical Equipment Co., Ltd.; Visual Sonics Vevo2100 high-resolution small animal ultrasound imaging system (equipped with MS-201 high-frequency linear array probe, with a transmission center frequency of 9-18 MHz), Japan FUJIFILM Co., Ltd.; MPIAS-500 multimedia color pathology image and text analysis system, Beijing Zhengheng Bocheng Technology Development Co., Ltd. Bruker Daltonics ImagePrep matrix electronic sprayer (Bremen, Germany), Epson Perfection V550 photo scanner (Epson Inc, Suwa, Japan), FlexAnalysis (Bruker, Germany) 3.4 software, and Bruker MALDI-TOF-MS (Bruker Daltonics, Berman, Germany). GET-Sprayer (I) (HIT Co., Ltd, Beijing).

[0140] 2. Methods

[0141] 2.1 Experimental groups and drug administration

[0142] SPF male SD rats weighing between 200-240g were randomly divided into 7 groups after 3 days of adaptive feeding. They were sham group (Sham), model group (Model), Nicorandil tablets group (NIC, 5mg / kg), Tongxinluo capsule group (TXL, 1g / kg), Shuangshen Ningxin capsule 90mg / kg group (SSNX90mg / kg, this dose is abbreviated as SSNX for subsequent mechanism research), Shuangshen Ningxin 45mg / kg group (SSNX 45mg / kg). Each drug-dosing group was pre-administered by gavage at 1mL / 100g for 7 days, and the sham group and model group were given an equal volume of sterile water. The model was prepared 2h after the last administration.

[0143] 2.2 Preparation of rat heart failure model

[0144] Myocardial ischemia-reperfusion / injury (MIRI) was used to establish a rat model of cardiac insufficiency. Rats were anesthetized with 3.5% sodium pentobarbital (10 mL / kg) intraperitoneally, and then the skin was routinely prepared. The rats were fixed in the supine position, intubated, and connected to a small animal ventilator for ventilation and breathing assistance. The electrocardiogram was connected according to the instructions for use of the electrocardiogram. The skin was incised obliquely and longitudinally at the 3rd to 4th intercostal space on the left side of the rat's chest. The muscles were gently separated with a hemostatic forceps. After the 4th rib was exposed, it was cut longitudinally from the middle of the rib. The rat's chest was opened from the direction perpendicular to the ribs using a chest opener, and the pericardium was gently cut open to fully expose the heart. A No. 0 surgical thread was inserted about 2 mm below the bifurcation of the left anterior descending branch of the coronary artery at the lower edge of the auricle. After stabilization for 1 minute, a plastic hose was placed at the knot and tied into a slipknot. The chest was then closed and the electrocardiogram was observed. The ischemia was successful when the QRS amplitude increased, the ST segment was elevated, and the T wave was tall or inverted. 45 minutes after ligation, the ligature was untied, the plastic hose was removed, leaving the thread ends, and the reperfusion process was achieved. The chest wall was sutured and the animals recovered spontaneous breathing. The sham operation group only threaded the thread without ligation, and the other groups were operated in the same way as the model group.

[0145] 2.3 Echocardiography to detect cardiac function and myocardial perfusion

[0146] After 3 hours of coronary reperfusion, rats were anesthetized by intraperitoneal injection of sodium pentobarbital. Rats were fixed in supine position, and the left anterior chest area of ​​rats was extensively prepared with coupling agent. When the heart rhythm of rats tended to be continuous and stable, the detection began. The high-frequency probe was positioned, and the cardiac motion was observed by M-mode echocardiography in the long axis of the left ventricle and the short axis of the parasternal section. The left ventricular long axis section was used to calculate the left ventricular end-diastolic diameter (LVIDd), left ventricular end-systolic diameter (LVIDs), left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), left ventricular ejection fraction (LVEF), left ventricular shortening fraction (FS), and left ventricular ejection fraction (EF). The average value of the values ​​measured in 5 consecutive cardiac cycles was selected for each index.

[0147] Then, sulfur hexafluoride microbubbles were prepared, and physiological saline for injection, i.e., 5 mL of 0.9% (w / v) sterile sodium chloride injection, was injected into the inner vial. The bottle was shaken vigorously until the lyophilized powder was completely dispersed, and the microbubble suspension was drawn into a 1 mL syringe. Self-contained nonlinear acoustic contrast was used, and high-frequency probe positioning was used. On the basis of the M-mode mode of the long axis section of the left ventricle, 0.4 mL of sulfur hexafluoride microbubbles were injected into the tail vein of each rat. The perfusion of the contrast agent in the heart was recorded while the contrast agent was injected, and the peak time of the contrast agent (sulfur hexafluoride microbubbles) in the heart detection area was analyzed.

[0148] 2.4 Observation of myocardial infarction area and no-reflow area in rats by TTC staining and thioflavin staining

[0149] After 3 hours of coronary reperfusion in rats, the abdominal aorta was exposed, and then the chest cavity was opened. 6% thioflavin dye was slowly injected through the abdominal aorta. After 1 minute, the ligature left at the surgical ligature position was re-ligated, and 2% Evans blue dye was slowly injected through the abdominal aorta again. After 10 seconds, when the myocardial tissue showed blue dye, the heart was quickly removed, and the excess dye and blood were rinsed with saline. Five slices of myocardium were evenly cut from the ligature line, each slice was about 2-3 mm thick, and the heart slices were placed under fluorescence, and 5 slices were photographed using a multimedia pathology image analysis system. The front and back images of the myocardium are the Evans blue and thioflavin staining images. After the shooting, turn off the fluorescent light, put the heart into 2,3,5-triphenyltetrazolium chloride (TTC) dye solution, and stain it at 37℃ in the dark for 15 minutes. Use gauze to absorb the residual moisture of the myocardium, flatten the cross section, and place it in a transparent glass dish containing clean pure water. Turn on the light, add a stable and consistent light source, and then use the multimedia pathology image analysis system to shoot the front and back images of 5 slices of myocardium, which are the Evans blue staining and TTC staining images. Then use Image-Pro Plus 6.0 software to analyze the pictures. Calculate the percentage of the ligation area, the percentage of no reflow area (thioflavin is not stained), and the percentage of myocardial infarction area (compared with the total myocardial area).

[0150] 2.4 Serum CK, CK-MB and LDH activity determination

[0151] After 3 h of coronary reperfusion, 3 mL of blood was collected from the abdominal aorta of the rats and allowed to stand at room temperature for 1 h at 3000 r / min. -1 After centrifugation for 15 min, the serum was separated and the activities and contents of creatine kinase (CK), creatine kinase isoenzyme (CK-MB) and lactate dehydrogenase (LDH) were detected using an automatic biochemical analyzer according to the instructions of the kit.

[0152] 2.5 Serum cAMP, cGMP, ATP, ADP, and AMP levels

[0153] Rats in the sham operation group, model group and Shuangshen Ningxin capsule 90 mg / kg group were selected for the determination of serum energy metabolism-related molecules. Blood was collected from the abdominal aorta 3 hours after coronary reperfusion in rats, serum was routinely prepared, and ELISA was used to detect cAMP, cGMP, ATP, ADP, and AMP. The methods were carried out according to the steps in the respective instructions.

[0154] 2.6 Mass spectrometry imaging to detect the distribution of energy metabolism molecules in myocardial tissue

[0155] Rats in the sham operation group, model group, and Shuangcan Ningxin capsule 90 mg / kg group were selected for mass spectrometry imaging studies. After the experiment, the rat hearts were snap-frozen in liquid nitrogen and frozen into 20-micron slices on a cryostat at -20°C. Serial tissue sections were immediately thawed and mounted on the conductive surface of an indium tin oxide-coated microscope glass slide. Then, 12 mg / mL of 2-MBT was prepared in a ratio of 80:20 (v / v) MeOH:water containing 0.2% TFA. The matrix solution was then sprayed onto the slices using a GET-Sprayer (I). Optical images of the slices were obtained using an Epson Perfection V550 photo scanner. H&E staining was performed to obtain standard histological optical images.

[0156] Mass spectrometry imaging information was initially observed and processed using Bruker FlexAnalysis 3.4 software. After generating and exporting the monomer peak list, the measured m / z values ​​were searched for possible metabolite identities using two metabolome databases (METLIN37 and LIPID MAPS38,39). To obtain MALDI-MS analysis data, mass spectra were recorded by 20 laser scans, each of which was accumulated by 500 laser shots. A laser raster size of 100 μm was used in situ to detect endogenous low molecular weight compounds in rat myocardial tissue sections. The cubic enhancement mode was selected for calibration. Finally, the compounds were identified.

[0157] 2.7 Statistical analysis

[0158] The experimental data were statistically analyzed using SPSS16.0 software. The experimental data of each group were expressed as mean±standard deviation (±s) after passing the homogeneity of variance test. One-way ANOVA was used for comparison among multiple groups; two independent sample t-test (T-Test) was used for pairwise comparison. P<0.05 was considered statistically significant.

[0159] 3. Results

[0160] 3.1 Effects on echocardiographic parameters in rats with heart failure

[0161] The results of cardiac ultrasound examination showed that compared with the sham operation group, the cardiac function indicators ejection fraction (EF), fractional shortening (FS), cardiac output (CO), and left ventricular anterior wall systolic thickness (LVAWs) in the model group were significantly reduced (P < 0.05-0.01), and the stroke volume (SV) and left ventricular anterior wall diastolic thickness (LVAWd) also showed a downward trend, indicating that the model animals had heart failure. Compared with the model group, the EF, FS, and LVAWs of the SSNX 90mg / kg, SSNX 45mg / kg, NIC, and TXL groups were significantly increased (P < 0.05-0.01), and CO, SV, and LVAWd all showed an upward trend. Figure 5 , Figure 6 .

[0162] 3.2 Effects on the peak time of myocardial blood perfusion in rats with heart failure

[0163] The results of myocardial ultrasound contrast showed that the contrast agent sulfur hexafluoride microbubbles were injected from the rat tail vein, and the echo filled the heart cavity after the cardiac cavity was developed. Compared with the sham operation group, the peak time of myocardial blood perfusion in the model group was significantly increased (P < 0.01); compared with the model group, the peak time of myocardial blood perfusion in the SSNX 90mg / kg, SSNX 45mg / kg, NIC and TXL groups was significantly reduced (P < 0.01), as shown in Figure 2. Figure 7 , Figure 8 .

[0164] 3.3 Effects on myocardial infarction area and no-reflow area in rats with heart failure

[0165] In the Evans blue + TTC staining image of the rat myocardium, the Evans blue stained area is the non-ischemic area, the Evans blue unstained area is the ischemic risk area (ischemic area) of surgical ligation, and the gray-white area is the TTC stained area, indicating the infarction area; there is no significant difference in the percentage of myocardial ischemic area among the groups, indicating that the size of the surgical ligation area is basically the same; no gray-white infarction area appeared in the myocardial muscle of the rats in the sham operation group. Compared with the sham operation group, the infarction area in the model group increased significantly (P < 0.01). Compared with the model group, the infarction area can be seen by naked eye observation in the NIC group, TXL group, SSNX90mg / kg, and 45mg / kg group. The NIC group, TXL group, SSNX90mg / kg, and 45mg / kg groups can effectively reduce the myocardial infarction area of ​​rats (P < 0.01). Among them, the SSNX90mg / kg group has a better effect on reducing the infarction area than the SSNX45 mg / kg group, as shown in Figure 2. Fig. 9 .

[0166] Thioflavin staining results of rat myocardium Fig.13As shown: the dark blue area is the no-reflow area, and the yellow area is not colored. No-reflow area was observed in the myocardial muscle of the rats in the sham operation group, while the other groups had no-reflow areas to varying degrees. Compared with the sham operation group, the no-reflow area in the model group increased significantly (P < 0.01). Compared with the model group, the no-reflow area in the NIC group, TXL group, SSNX90mg / kg, and 45mg / kg groups decreased significantly (P < 0.01). The effect of reducing the no-reflow area in the SSNX90mg / kg group was better than that in the SSNX45mg / kg group, as shown in Figure 2. Fig.10 .

[0167] 3.4 Effects on serum myocardial enzymes CK, CK-MB and LDH in rats

[0168] The levels of serum CK, CK-MB, and LDH in the model group were significantly higher than those in the sham operation group (P < 0.01-0.05). Compared with the model group, the levels of serum CK, CK-MB, and LDH in the NIC group, TXL group, SSNX 90 mg / kg group, and SSNX 45 mg / kg group were all lower (P < 0.05-0.01). Fig.11 .

[0169] 3.5 Effects on rat serum cAMP, cGMP, ATP, ADP, and AMP

[0170] The results of the detection of cAMP, cGMP, ATP, ADP and AMP in rat serum showed that compared with the Sham group, the ATP, AMP and cAMP contents in the Model group were significantly decreased (P < 0.01), the cGMP content was significantly increased (P < 0.01), and the ADP content had an increasing trend, with no statistical difference; compared with the Model group, the cGMP and ADP contents in the serum of rats in the SSNX group and the TG group were significantly decreased (P < 0.01), and the cAMP, ATP and AMP contents were significantly increased (P < 0.01), with statistically significant differences. Fig.12 .

[0171] 3.5 Effects on ATP, ADP, AMP, GTP, GDP and GMP in rat myocardial tissue

[0172] The results of mass spectrometry imaging of ATP, ADP, AMP, GTP, GDP, and GMP in rat myocardial tissue showed that a black-and-white image of the shape of the myocardial tissue slice was taken under an optical microscope, and HE staining of the frozen section of the myocardial section corresponding to the mass spectrometry imaging detection was performed. The blue arrow in the HE staining image points to the ischemic infarction area (the area where the myocardial color becomes lighter) ( Fig.13 A); Mass spectrometry imaging and quantitative analysis results showed that the distribution of ATP in the ischemic infarction area of ​​the model group decreased, while the distribution of ATP in the ischemic infarction area of ​​the SSNX group increased significantly ( Fig.13A). The relative expression levels of ATP, ADP, AMP, GTP, GDP and GMP in each group were compared and statistically analyzed. Fig.13 B. Compared with the sham group, the levels of AMP, ATP, and GTP in the whole cross section of the heart tissue of the model group rats were lower (P < 0.01, P < 0.01, and P < 0.05, respectively), ADP and GMP did not change significantly, while GDP increased significantly (P < 0.05). Compared with the model group, the levels of AMP, ATP, and GTP in the SSNX group were higher (P < 0.01, P < 0.01, and P < 0.01, respectively). The GDP level was also higher, while the ADP and GMP levels were significantly lower (P < 0.01 and P < 0.01, respectively). Atkinson and Walton proposed in 1998: Energy charge = ([ATP] + 1 / 2 [ADP]) / ([ATP] + [ADP] + [AMP]); [ATP] + [ADP] + [AMP] refers to the concentration of the total adenosine system (the sum of ATP, ADP, and AMP). [ATP] + 1 / 2 [ADP] refers to the concentration of ATP and equivalent ATP. The production and consumption of ATP occurs according to the state of energy charge in the cell. When the energy charge is high, the ATP production process is inhibited and the ATP utilization process is stimulated. When the energy charge is low, the effect is the opposite. The distribution of myocardial AMP, ADP, ATP, GMP, GDP and GTP in rats with myocardial ischemia-reperfusion injury was significantly abnormal. After SSNX treatment, myocardial ATP production increased, AMP content increased, and energy charge decreased. Compared with the model group, it was in a low energy charge state and ATP production increased. According to the energy charge calculation formula, it was found that the myocardial tissue energy charge in the SSNX and TG treatment groups decreased, and the energy capacity in the myocardium increased ( Fig.13 C).

[0173] 4. Discussion and Results

[0174] Heart failure is an abnormality of cardiac systolic and diastolic function caused by different causes, so that when the circulating blood volume and vasomotor function are normal, the blood pumped by the heart cannot meet the needs of the tissues. Heart failure is not the same as heart failure. Heart failure includes heart failure, and heart failure is the final stage of heart failure. Heart failure is a process from compensation to decompensation, while heart failure has reached the decompensation stage. Myocardial ischemia and (or) myocardial infarction in coronary heart disease are one of the most common causes of heart failure. Myocardial ischemia-reperfusion injury (MIRI) is a pathological process in which the ischemic myocardium is restored to normal perfusion when reperfusion is restored within a certain period of time after partial or complete acute occlusion of the coronary artery. However, its tissue damage will be progressively aggravated. MIRI is often manifested as arrhythmia, increased myocardial enzyme leakage, decreased cardiac function, etc. MIRI is a complex process involving multiple signal transduction pathways and cell regulatory factors. At present, its pathogenesis has not been fully elucidated. The beating of the heart consumes a large amount of ATP to transport blood and oxygen throughout the body and maintain the vital activities of organs throughout the body. Mitochondria are key organelles for maintaining intracellular homeostasis. They produce most of the ATP used by cells through oxidative phosphorylation to maintain cell metabolism. Previous studies have found that the pathogenesis of MIRI includes excessive oxygen free radicals, intracellular calcium overload, rapid changes in cellular pH, opening of mitochondrial permeability transition pores, energy metabolism disorders, and inflammatory responses. Ischemia and hypoxia induce impaired mitochondrial function, and energy metabolism disorders are the initial link of MIRI.

[0175] This application uses a rat model of myocardial ischemia-reperfusion injury to study the improvement of Shuangshen Ningxin Capsule (SSNX) on heart failure from the perspective of energy metabolism. The results show that the Chinese medicine composition of this application can significantly reduce the level of myocardial enzymes in myocardial injury and reduce the area of ​​myocardial infarction; increase the content of cAMP, AMP, and ATP in rat serum, and reduce the content of serum cGMP and ADP; myocardial ATP generation increases, AMP content increases, and energy charge decreases, which is in a low energy charge state compared with the model group, and ATP generation increases; and then improves the cardiac function of MIRI rats, achieving the effect of reducing the development of heart failure and improving heart function. It can be seen that the Chinese medicine composition of this application can play a protective role against heart failure by improving rat myocardial energy metabolism and increasing ATP generation.

Claims

1. Use of a Chinese medicine composition in the preparation of a drug for treating and / or preventing heart failure or heart failure with a left ventricular ejection fraction of less than 40%, the Chinese medicine composition being prepared from the following medicinal materials in parts by weight: 1-2 parts of ginseng, 1-2 parts of salvia miltiorrhiza, and 6-8 parts of Corydalis yanhusuo; The Chinese medicine composition is prepared by the following method: extracting ginseng, salvia miltiorrhiza and corydalis yanhusuo with ethanol or 60% to 70% ethanol aqueous solution by volume, respectively, mixing the obtained ginseng extract, salvia miltiorrhiza extract and corydalis yanhusuo extract to obtain the Chinese medicine composition.

2. The use according to claim 1, wherein the weight ratio of ginseng, salvia miltiorrhiza and Corydalis yanhusuo is: 1.7 parts of ginseng, 1 part of salvia miltiorrhiza and 6.9 parts of Corydalis yanhusuo.

3. The use as claimed in claim 1, wherein the traditional Chinese medicine composition is prepared by the following method: extracting ginseng, salvia miltiorrhiza, and Corydalis yanhusuo with ethanol or ethanol aqueous solution respectively, purifying the ginseng extract, salvia miltiorrhiza extract, and Corydalis yanhusuo extract with resin, and mixing the obtained ginseng extract, salvia miltiorrhiza extract, and Corydalis yanhusuo extract to obtain the traditional Chinese medicine composition.

4. The method according to claim 3, wherein the resin is a macroporous adsorption resin.

5. The use according to claim 3, wherein the ginseng extract is purified by AB-8 macroporous adsorption resin, the salvia miltiorrhiza extract is purified by KLY-134 macroporous adsorption resin, and the Corydalis yanhusuo extract is purified by AB-8 macroporous adsorption resin.

6. The method of claim 3, wherein the purification comprises eluting with water to remove impurities and collecting the ethanol elution portion.

7. The use according to claim 1, wherein the Chinese medicine composition is prepared by the following method: Take ginseng, extract with 60% ethanol by refluxing to obtain an extract, concentrate under reduced pressure, purify the concentrate with AB-8 macropore, elute with water, then elute with 10% ethanol, discard the eluate with water and 10% ethanol, continue to elute with 70% ethanol, collect the eluate with 70% ethanol, and obtain ginseng extract; Take Danshen, extract with 60% ethanol by refluxing to obtain an extract, concentrate under reduced pressure, purify the concentrate with KLY-134 macroporous adsorption resin, elute with water, and then elute with 60% ethanol, discard the water eluate, collect the 60% ethanol eluate, and obtain Danshen extract; Take Corydalis yanhusuo, extract with 70% ethanol under reflux to obtain an extract, concentrate under reduced pressure, purify the concentrate with AB-8 macroporous adsorption resin, elute with water, then elute with 80% ethanol, discard the water eluate, collect the 80% ethanol eluate, and obtain the Corydalis yanhusuo extract; The ginseng extract, salvia miltiorrhiza extract and Corydalis yanhusuo extract are combined to obtain the traditional Chinese medicine composition.

8. The use according to claim 7, wherein the heart failure is caused by myocardial energy metabolism disorder or myocardial microcirculation disorder.

9. The use according to claim 1, wherein the heart failure is chronic or acute heart failure.

10. The use according to claim 1, wherein the heart failure is chronic heart failure.